2421_Ch17.ppt
... antibodies are found in the serum of the blood of immune animals or individuals. Serum: fluid portion of blood antisera is a generic term for blood-derived fluids containing antibodies serology is the study of reactions between antibodies and antigens the protein fractions are called globulins (fig. ...
... antibodies are found in the serum of the blood of immune animals or individuals. Serum: fluid portion of blood antisera is a generic term for blood-derived fluids containing antibodies serology is the study of reactions between antibodies and antigens the protein fractions are called globulins (fig. ...
Endocrine Review Endocrine glands don`t have ______ and secrete
... ___________ . TH and the androgens are different from hormones like insulin that they are not ___________ . Because of this, they can cross the lipid ___________ and instigate changes within the cell. For example, TH affect the ___________ and ___________ of target cells to cause and increase in met ...
... ___________ . TH and the androgens are different from hormones like insulin that they are not ___________ . Because of this, they can cross the lipid ___________ and instigate changes within the cell. For example, TH affect the ___________ and ___________ of target cells to cause and increase in met ...
Freeman 1e: How we got there
... on the surfaces of all nucleated cells. • Class II MHC proteins are found only on the surface of B lymphocytes, macrophages, and dendritic cells, all of which are APCs (Figure 22.11). ...
... on the surfaces of all nucleated cells. • Class II MHC proteins are found only on the surface of B lymphocytes, macrophages, and dendritic cells, all of which are APCs (Figure 22.11). ...
Immune Tolerance
... distinct subtypes of CD4+ T cell: T regulatory 1 (TR1) cells, which secrete high levels of IL-10, no IL-4 and no or low levels of IFN-; and T helper 3 (TH3) cells, which secrete high levels of TGF-. Although CD8+ T cells are normally associated with cytotoxic T-lymphocyte function and IFN- productio ...
... distinct subtypes of CD4+ T cell: T regulatory 1 (TR1) cells, which secrete high levels of IL-10, no IL-4 and no or low levels of IFN-; and T helper 3 (TH3) cells, which secrete high levels of TGF-. Although CD8+ T cells are normally associated with cytotoxic T-lymphocyte function and IFN- productio ...
Week 9: Today`s Program
... Vertebrate lymphocytes take on specialized roles Circulate through blood & lymph, concentrated in spleen & lymph nodes B & T cells bear ~100K antigen receptors (all the same) Antigenbinding sites ...
... Vertebrate lymphocytes take on specialized roles Circulate through blood & lymph, concentrated in spleen & lymph nodes B & T cells bear ~100K antigen receptors (all the same) Antigenbinding sites ...
BLA Biology (2016-17)
... 3. Helper T- Cell recognizes antigen on the surface of the macrophage and becomes active. 4. Active Helper T-Cell activates Cytotoxic T-Cells and B-Cells. 5. Cytotoxic T-Cells divide into Active Cytotoxic T-cells and Memory T – Cells. 6. Active Cytotoxic T-Cells kill infected cells. 7. At the same t ...
... 3. Helper T- Cell recognizes antigen on the surface of the macrophage and becomes active. 4. Active Helper T-Cell activates Cytotoxic T-Cells and B-Cells. 5. Cytotoxic T-Cells divide into Active Cytotoxic T-cells and Memory T – Cells. 6. Active Cytotoxic T-Cells kill infected cells. 7. At the same t ...
Module 12 Notes
... o Edward Jenner developed ___________________ vaccine in 1798 Development of vaccines most important application of microbiology o Jenner’s work won him Nobel Prize Principles and Effects of Vaccination Main purpose of vaccination stimulate ____________________________ production o Vaccine for ...
... o Edward Jenner developed ___________________ vaccine in 1798 Development of vaccines most important application of microbiology o Jenner’s work won him Nobel Prize Principles and Effects of Vaccination Main purpose of vaccination stimulate ____________________________ production o Vaccine for ...
The Immune System - University of Arizona
... • Perhaps the most studied feature of the IgG isotypes is their ability to activate the classical complement pathway. • Although all four are capable of initiating the classical cascade, they do so to varying degrees (G3>G1>G2>G4). ...
... • Perhaps the most studied feature of the IgG isotypes is their ability to activate the classical complement pathway. • Although all four are capable of initiating the classical cascade, they do so to varying degrees (G3>G1>G2>G4). ...
Cancer Immunology_4
... During tumour progression, tumour variants may evolve that upregulate ligands for inhibitory receptors and/or lose ligands for activating receptors. These tumours may escape NK-cellmediated recognition. NK cells can be also targeted to IgG antibodycoated tumor cells by Fc receptors (CD16). ...
... During tumour progression, tumour variants may evolve that upregulate ligands for inhibitory receptors and/or lose ligands for activating receptors. These tumours may escape NK-cellmediated recognition. NK cells can be also targeted to IgG antibodycoated tumor cells by Fc receptors (CD16). ...
Lymphatic System
... Usually less than 2.5 cm long Bean shaped FUNCTIONS: Filters potentially harmful particles ...
... Usually less than 2.5 cm long Bean shaped FUNCTIONS: Filters potentially harmful particles ...
Chapter 35
... Memory and Effector Cells • When a B or T cell is stimulated to divide, it produces more than one cell type ...
... Memory and Effector Cells • When a B or T cell is stimulated to divide, it produces more than one cell type ...
Evelien Smits, UZ Antwepen
... • However: - Many cancer types are resistant - Significant percentage of patients do not respond ...
... • However: - Many cancer types are resistant - Significant percentage of patients do not respond ...
versus hydrocortisone treatment in late
... relieved early and efficiently by spontaneous autodecompression or therapeutic interventions such as immunomodulatory measures or surgical decompression, permanent tissue changes will ensue, causing restriction of extraocular muscles, connective tissue fibrosis and optic nerve damage. Clinically, cl ...
... relieved early and efficiently by spontaneous autodecompression or therapeutic interventions such as immunomodulatory measures or surgical decompression, permanent tissue changes will ensue, causing restriction of extraocular muscles, connective tissue fibrosis and optic nerve damage. Clinically, cl ...
IMMUNOBIOLOGY (PCB4233 - 3 credits) Instructor Dr. Mauricio
... Plagiarism is a serious offence will not be taken lightly. Plagiarism can be intentional (copying another student’s work, collaborating too closely with another student) or unintentional (not citing all references, collaborating too closely with another student.) The best ways to avoid unintentional ...
... Plagiarism is a serious offence will not be taken lightly. Plagiarism can be intentional (copying another student’s work, collaborating too closely with another student) or unintentional (not citing all references, collaborating too closely with another student.) The best ways to avoid unintentional ...
Introduction To Immunology - Dow University of Health Sciences
... provide immediate protection and Vaccine to provide long term protection These preparations should be given at different sites in the body to prevent the antibodies from neutralizing the immunogen in the vaccine. This approach is used in the prevention of Tetanus, Rabies and Hepatitis B ...
... provide immediate protection and Vaccine to provide long term protection These preparations should be given at different sites in the body to prevent the antibodies from neutralizing the immunogen in the vaccine. This approach is used in the prevention of Tetanus, Rabies and Hepatitis B ...
Immunotherapy - Sara M. Engh
... http://www.webmd.com/cancer/news/20141104/immunotherapy-brings-new-hope-cancer-fight FDA Grants Breakthrough Therapy Designation to Roche's Lung Cancer Immunotherapy. (2015, February). In Drug Discovery & Development. Retrieved February 16, 2015 from http://www.dddmag.com/news/2015/02/fda-grants-bre ...
... http://www.webmd.com/cancer/news/20141104/immunotherapy-brings-new-hope-cancer-fight FDA Grants Breakthrough Therapy Designation to Roche's Lung Cancer Immunotherapy. (2015, February). In Drug Discovery & Development. Retrieved February 16, 2015 from http://www.dddmag.com/news/2015/02/fda-grants-bre ...
File
... secrete cytokines to activate phagocytes, T cells and B cells destroy infected cells by apoptosis phagocytes which capture the pathogen and display fragments of the antigen on their surface production of a clone of Helper T cell Lymphocytes that move to the site of ...
... secrete cytokines to activate phagocytes, T cells and B cells destroy infected cells by apoptosis phagocytes which capture the pathogen and display fragments of the antigen on their surface production of a clone of Helper T cell Lymphocytes that move to the site of ...
Blood, Lymph and Immune Systems
... • primary role: changes lymphocytes to T cells for cellular immunity ...
... • primary role: changes lymphocytes to T cells for cellular immunity ...
Cancer immunotherapy
Cancer immunotherapy (immuno-oncology) is the use of the immune system to treat cancer. Immunotherapies fall into three main groups: cellular, antibody and cytokine. They exploit the fact that cancer cells often have subtly different molecules on their surface that can be detected by the immune system. These molecules, known as cancer antigens, are most commonly proteins, but also include molecules such as carbohydrates. Immunotherapy is used to provoke the immune system into attacking the tumor cells by using these antigens as targets.Antibody therapies are the most successful immunotherapy, treating a wide range of cancers. Antibodies are proteins produced by the immune system that bind to a target antigen on the cell surface. In normal physiology the immune system uses them to fight pathogens. Each antibody is specific to one or a few proteins. Those that bind to cancer antigens are used to treat cancer. Cell surface receptors are common targets for antibody therapies and include the CD20, CD274, and CD279. Once bound to a cancer antigen, antibodies can induce antibody-dependent cell-mediated cytotoxicity, activate the complement system, or prevent a receptor from interacting with its ligand, all of which can lead to cell death. Multiple antibodies are approved to treat cancer, including Alemtuzumab, Ipilimumab, Nivolumab, Ofatumumab, and Rituximab.Cellular therapies, also known as cancer vaccines, usually involve the removal of immune cells from the blood or from a tumor. Immune cells specific for the tumor are activated, cultured and returned to the patient where the immune cells attack the cancer. Cell types that can be used in this way are natural killer cells, lymphokine-activated killer cells, cytotoxic T cells and dendritic cells. The only cell-based therapy approved in the US is Dendreon's Provenge, for the treatment of prostate cancer.Interleukin-2 and interferon-α are examples of cytokines, proteins that regulate and coordinate the behaviour of the immune system. They have the ability to enhance anti-tumor activity and thus can be used as cancer treatments. Interferon-α is used in the treatment of hairy-cell leukaemia, AIDS-related Kaposi's sarcoma, follicular lymphoma, chronic myeloid leukaemia and malignant melanoma. Interleukin-2 is used in the treatment of malignant melanoma and renal cell carcinoma.